REGN
Regeneron Pharmaceuticals, Inc. NASDAQ Listed Apr 2, 1991$708.93
Mkt Cap $73.0B
52w Low $476.49
67.4% of range
52w High $821.11
50d MA $751.47
200d MA $686.11
P/E (TTM)
16.3x
EV/EBITDA
13.8x
P/B
2.4x
Debt/Equity
0.1x
ROE
14.1%
P/FCF
19.8x
RSI (14)
—
ATR (14)
—
Beta
0.40
50d MA
$751.47
200d MA
$686.11
Avg Volume
688.9K
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
777 Old Saw Mill River Road · Tarrytown, NY 10591-6707 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | TNS | 8.91 | 9.47 | +6.3% | 686.36 | +1.0% | +3.0% | -0.8% | +1.1% | -1.0% | +2.7% | — |
| Jan 30, 2026 | TNS | 10.74 | 11.44 | +6.5% | 741.45 | -1.2% | +1.8% | +0.6% | +2.1% | -1.1% | +2.5% | — |
| Oct 28, 2025 | TNS | 9.65 | 11.83 | +22.6% | 654.48 | -0.6% | -0.2% | +0.2% | -0.3% | -1.5% | -2.2% | — |
| Aug 1, 2025 | TNS | 8.43 | 12.89 | +52.9% | 558.87 | +1.5% | +2.3% | -0.3% | -2.6% | +0.8% | +0.6% | — |
| Apr 29, 2025 | TNS | 8.62 | 8.22 | -4.6% | 568.91 | +1.8% | +5.2% | -1.5% | +2.6% | -0.3% | -7.5% | — |
| Feb 4, 2025 | TNS | 11.21 | 12.07 | +7.7% | 697.05 | +1.7% | +2.8% | +0.7% | -1.7% | -2.8% | -3.6% | — |
| Oct 31, 2024 | TNS | 11.69 | 12.46 | +6.6% | 838.20 | +0.8% | +0.6% | -1.7% | +0.1% | -1.5% | +1.0% | — |
| Aug 1, 2024 | TNS | 10.61 | 11.56 | +9.0% | 1093.14 | +0.6% | -1.0% | -1.0% | -0.5% | +0.2% | +4.3% | — |
| May 2, 2024 | TNS | 10.17 | 9.55 | -6.1% | 937.61 | -1.1% | +2.1% | +0.2% | +1.2% | -1.5% | +1.3% | — |
| Feb 2, 2024 | TNS | 10.73 | 11.86 | +10.5% | 945.18 | -1.4% | -0.9% | +0.2% | +0.1% | +0.8% | +0.7% | — |
| Nov 2, 2023 | TNS | 10.72 | 11.59 | +8.1% | 818.79 | +2.4% | -0.2% | +1.9% | -0.2% | -1.0% | -2.7% | — |
| Aug 3, 2023 | TNS | 9.84 | 10.24 | +4.1% | 771.45 | +0.6% | -0.6% | +1.1% | +0.7% | +0.7% | +0.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Guggenheim | Maintains | Buy → Buy | — | $707.06 | $703.02 | -0.6% | -0.8% | +1.1% | -1.0% | +2.7% | -1.7% |
| Apr 30 | Barclays | Maintains | Overweight → Overweight | — | $686.36 | $693.08 | +1.0% | +3.0% | -0.8% | +1.1% | -1.0% | +2.7% |
| Apr 30 | Truist | Maintains | Buy → Buy | — | $686.36 | $693.08 | +1.0% | +3.0% | -0.8% | +1.1% | -1.0% | +2.7% |
| Apr 30 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $686.36 | $693.08 | +1.0% | +3.0% | -0.8% | +1.1% | -1.0% | +2.7% |
| Apr 30 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $686.36 | $693.08 | +1.0% | +3.0% | -0.8% | +1.1% | -1.0% | +2.7% |
| Apr 23 | TD Cowen | Maintains | Buy → Buy | — | $746.58 | $750.99 | +0.6% | +2.6% | -1.9% | -0.9% | -1.7% | -6.2% |
| Apr 23 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $746.58 | $750.99 | +0.6% | +2.6% | -1.9% | -0.9% | -1.7% | -6.2% |
| Apr 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $767.85 | $771.48 | +0.5% | -2.5% | -0.3% | +1.2% | -0.2% | -1.1% |
| Apr 8 | Bernstein | Maintains | Outperform → Outperform | — | $760.27 | $765.26 | +0.7% | +2.0% | -1.0% | -2.5% | -0.3% | +1.2% |
| Mar 31 | Truist | Maintains | Buy → Buy | — | $749.29 | $757.47 | +1.1% | +3.1% | +0.6% | -2.0% | +0.2% | -0.4% |
| Mar 2 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $781.67 | $771.10 | -1.4% | +1.2% | -3.1% | +2.7% | -2.9% | -0.7% |
| Feb 9 | Guggenheim | Maintains | Buy → Buy | — | $785.51 | $783.17 | -0.3% | -0.7% | -3.3% | +3.2% | +0.6% | +2.5% |
| Feb 2 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $741.45 | $732.92 | -1.2% | +1.8% | +0.6% | +2.1% | -1.1% | +2.5% |
| Feb 2 | JP Morgan | Maintains | Overweight → Overweight | — | $741.45 | $732.92 | -1.2% | +1.8% | +0.6% | +2.1% | -1.1% | +2.5% |
| Feb 2 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $741.45 | $732.92 | -1.2% | +1.8% | +0.6% | +2.1% | -1.1% | +2.5% |
| Feb 2 | Truist | Maintains | Buy → Buy | — | $741.45 | $732.92 | -1.2% | +1.8% | +0.6% | +2.1% | -1.1% | +2.5% |
| Feb 2 | Oppenheimer | Maintains | Outperform → Outperform | — | $741.45 | $732.92 | -1.2% | +1.8% | +0.6% | +2.1% | -1.1% | +2.5% |
| Feb 2 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $741.45 | $732.92 | -1.2% | +1.8% | +0.6% | +2.1% | -1.1% | +2.5% |
| Jan 22 | Evercore ISI | Maintains | Outperform → Outperform | — | $749.33 | $750.34 | +0.1% | +0.8% | -0.3% | +1.2% | +1.1% | -2.6% |
| Jan 8 | Truist | Maintains | Buy → Buy | — | $812.27 | $805.81 | -0.8% | -1.4% | -0.6% | -3.6% | -1.2% | -0.6% |
| Jan 7 | BofA Securities | Upgrade | Underperform → Buy | — | $776.54 | $786.18 | +1.2% | +4.6% | -1.4% | -0.6% | -3.6% | -1.2% |
| Dec 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $746.80 | $741.59 | -0.7% | -0.7% | +1.5% | -0.8% | +0.5% | -0.1% |
| Dec 10 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $692.58 | $695.06 | +0.4% | +4.9% | +2.8% | -0.7% | +1.5% | -0.8% |
| Dec 4 | Canaccord Genuity | Maintains | Buy → Buy | — | $723.67 | $732.45 | +1.2% | -0.1% | -0.6% | -2.1% | -1.5% | +4.9% |
| Dec 4 | BMO Capital | Maintains | Outperform → Outperform | — | $723.67 | $732.45 | +1.2% | -0.1% | -0.6% | -2.1% | -1.5% | +4.9% |
| Dec 3 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $742.00 | $730.36 | -1.6% | -2.5% | -0.1% | -0.6% | -2.1% | -1.5% |
| Nov 24 | Scotiabank | Maintains | Sector Perform → Sector Perform | — | $755.90 | $759.05 | +0.4% | +0.7% | +3.4% | -0.3% | -0.6% | -3.9% |
| Nov 20 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $702.75 | $725.00 | +3.2% | +4.9% | +2.6% | +0.7% | +3.4% | -0.3% |
| Nov 7 | UBS | Maintains | Neutral → Neutral | — | $646.87 | $650.35 | +0.5% | +1.6% | -0.4% | +3.0% | +1.1% | +1.9% |
| Oct 29 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $654.48 | $650.41 | -0.6% | -0.2% | +0.2% | -0.3% | -1.5% | -2.2% |
| Oct 29 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $654.48 | $650.41 | -0.6% | -0.2% | +0.2% | -0.3% | -1.5% | -2.2% |
| Oct 29 | BofA Securities | Maintains | Underperform → Underperform | — | $654.48 | $650.41 | -0.6% | -0.2% | +0.2% | -0.3% | -1.5% | -2.2% |
| Oct 29 | Citigroup | Maintains | Buy → Buy | — | $654.48 | $650.41 | -0.6% | -0.2% | +0.2% | -0.3% | -1.5% | -2.2% |
| Oct 29 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $654.48 | $650.41 | -0.6% | -0.2% | +0.2% | -0.3% | -1.5% | -2.2% |
| Oct 29 | Guggenheim | Maintains | Buy → Buy | — | $654.48 | $650.41 | -0.6% | -0.2% | +0.2% | -0.3% | -1.5% | -2.2% |
| Oct 23 | Canaccord Genuity | Maintains | Buy → Buy | — | $584.74 | $579.68 | -0.9% | -1.5% | +0.4% | +1.3% | +11.8% | -0.2% |
| Oct 14 | Canaccord Genuity | Maintains | Buy → Buy | — | $557.73 | $556.92 | -0.1% | +2.7% | +0.7% | -1.3% | +1.6% | -0.2% |
| Oct 13 | Citigroup | Maintains | Buy → Buy | — | $564.63 | $551.50 | -2.3% | -1.2% | +2.7% | +0.7% | -1.3% | +1.6% |
| Oct 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $569.90 | $569.29 | -0.1% | -0.9% | -1.2% | +2.7% | +0.7% | -1.3% |
| Oct 8 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $583.24 | $584.01 | +0.1% | -3.3% | +1.1% | -0.9% | -1.2% | +2.7% |
| Aug 27 | Bernstein | Maintains | Outperform → Outperform | — | $587.65 | $591.87 | +0.7% | -0.1% | -1.3% | +0.2% | -0.5% | -2.4% |
| Aug 27 | Jefferies | Maintains | Buy → Buy | — | $587.65 | $591.87 | +0.7% | -0.1% | -1.3% | +0.2% | -0.5% | -2.4% |
| Aug 11 | Truist | Maintains | Buy → Buy | — | $563.00 | $561.52 | -0.3% | -3.0% | +1.9% | +0.9% | +0.8% | +2.6% |
| Aug 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $558.87 | $566.98 | +1.5% | +2.3% | -0.3% | -2.6% | +0.8% | +0.6% |
| Aug 4 | BMO Capital | Maintains | Outperform → Outperform | — | $558.87 | $566.98 | +1.5% | +2.3% | -0.3% | -2.6% | +0.8% | +0.6% |
| Aug 4 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $558.87 | $566.98 | +1.5% | +2.3% | -0.3% | -2.6% | +0.8% | +0.6% |
| Aug 4 | Guggenheim | Maintains | Buy → Buy | — | $558.87 | $566.98 | +1.5% | +2.3% | -0.3% | -2.6% | +0.8% | +0.6% |
| Jul 23 | Canaccord Genuity | Maintains | Buy → Buy | — | $560.93 | $568.12 | +1.3% | +2.0% | -1.4% | -0.3% | -0.8% | -0.1% |
| Jul 11 | UBS | Maintains | Neutral → Neutral | — | $559.76 | $558.39 | -0.2% | +1.4% | +0.5% | -4.0% | -0.0% | +0.4% |
| Jul 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $552.58 | $554.38 | +0.3% | +1.3% | +1.4% | +0.5% | -4.0% | -0.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | RYAN ARTHUR FDir | — | Sell | 1 | $712.09 | $712 | 17,505 | -0.98% | — |
| May 1, 2026 | RYAN ARTHUR FDir | — | Sell | 2 | $710.87 | $1K | 17,511 | -0.98% | — |
| May 1, 2026 | RYAN ARTHUR FDir | — | Sell | 6 | $709.45 | $4K | 17,513 | -0.98% | — |
| May 1, 2026 | RYAN ARTHUR FDir | — | Sell | 4 | $707.40 | $3K | 17,519 | -0.98% | — |
| May 1, 2026 | RYAN ARTHUR FDir | — | Sell | 7 | $706.74 | $5K | 17,523 | -0.98% | — |
| May 1, 2026 | RYAN ARTHUR FDir | — | Sell | 14 | $705.56 | $10K | 17,530 | -0.98% | — |
| May 1, 2026 | RYAN ARTHUR FDir | — | Sell | 24 | $703.46 | $17K | 17,559 | -0.98% | — |
| May 1, 2026 | RYAN ARTHUR FDir | — | Sell | 15 | $702.46 | $11K | 17,583 | -0.98% | — |
| May 1, 2026 | RYAN ARTHUR FDir | — | Sell | 5 | $701.76 | $4K | 17,598 | -0.98% | — |
8-K
Unknown — 8-K Filing
This boilerplate 8-K filing contains only standard legal disclaimers and forward-looking statement warnings, providing no material information about Regeneron's business operations or financial performance that would impact stock valuation.
Apr 8
8-K
Opko Health Inc. -- 8-K Filing
OPKO Health reported fourth-quarter 2025 results and is hosting a conference call to discuss financial performance and business developments with investors.
Feb 26
8-K · 5.02
!!! Very High
AtaiBeckley Inc. -- 8-K 5.02: Executive Change
AtaiBiomedicines appointed Michael Faerm as CFO and principal accounting officer, strengthening financial leadership amid the company's clinical development programs.
Feb 19
Data updated apr 26, 2026 10:23pm
· Source: massive.com